Dyslipidemia Fact Sheet in South Korea, 2022
- Author:
Eun-Sun JIN
1
;
Jee-Seon SHIM
;
Sung Eun KIM
;
Jae Hyun BAE
;
Shinae KANG
;
Jong Chul WON
;
Min-Jeong SHIN
;
Heung Yong JIN
;
Jenny MOON
;
Hokyou LEE
;
Hyeon Chang KIM
;
In-Kyung JEONG
;
Author Information
- Publication Type:Original Article
- From:Diabetes & Metabolism Journal 2023;47(5):632-642
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:This study aimed to investigate the prevalence and status of dyslipidemia management among South Korean adults, as performed by the Korean Society of Lipid and Atherosclerosis under the name Dyslipidemia Fact Sheet 2022.
Methods:We analyzed the lipid profiles, age-standardized and crude prevalence, management status of hypercholesterolemia and dyslipidemia, and health behaviors among Korean adults aged ≥20 years, using the Korea National Health and Nutrition Examination Survey data between 2007 and 2020.
Results:In South Korea, the crude prevalence of hypercholesterolemia (total cholesterol ≥240 mg/dL or use of a lipid-lowering drug) in 2020 was 24%, and the age-standardized prevalence of hypercholesterolemia more than doubled from 2007 to 2020. The crude treatment rate was 55.2%, and the control rate was 47.7%. The crude prevalence of dyslipidemia—more than one out of three conditions (low-density lipoprotein cholesterol ≥160 or the use of a lipid-lowering drug, triglycerides ≥200, or high-density lipoprotein cholesterol [HDL-C] [men and women] <40 mg/dL)—was 40.2% between 2016 and 2020. However, it increased to 48.2% when the definition of hypo-HDL-cholesterolemia in women changed from <40 to <50 mg/dL.
Conclusion:Although the prevalence of hypercholesterolemia and dyslipidemia has steadily increased in South Korea, the treatment rate remains low. Therefore, continuous efforts are needed to manage dyslipidemia through cooperation between the national healthcare system, patients, and healthcare providers.
